KR100959704B1 - 콜레스테롤 및 트리글리세리드의 감소에 사용하기 위한디아실글리세롤 및 피토스테롤 에스테르 강화 오일 - Google Patents
콜레스테롤 및 트리글리세리드의 감소에 사용하기 위한디아실글리세롤 및 피토스테롤 에스테르 강화 오일 Download PDFInfo
- Publication number
- KR100959704B1 KR100959704B1 KR1020057014677A KR20057014677A KR100959704B1 KR 100959704 B1 KR100959704 B1 KR 100959704B1 KR 1020057014677 A KR1020057014677 A KR 1020057014677A KR 20057014677 A KR20057014677 A KR 20057014677A KR 100959704 B1 KR100959704 B1 KR 100959704B1
- Authority
- KR
- South Korea
- Prior art keywords
- fatty acid
- acid esters
- oil
- phytosterol
- phytostanol
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 83
- 150000001982 diacylglycerols Chemical class 0.000 title claims abstract description 69
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 31
- 150000003626 triacylglycerols Chemical class 0.000 title claims abstract description 27
- 239000003921 oil Substances 0.000 title claims description 93
- 230000009467 reduction Effects 0.000 title claims description 6
- 229940075999 phytosterol ester Drugs 0.000 title description 7
- -1 fatty acid esters Chemical class 0.000 claims abstract description 175
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 149
- 229930195729 fatty acid Natural products 0.000 claims abstract description 149
- 239000000194 fatty acid Substances 0.000 claims abstract description 149
- 239000000203 mixture Substances 0.000 claims abstract description 100
- 210000002540 macrophage Anatomy 0.000 claims abstract description 82
- 239000004006 olive oil Substances 0.000 claims abstract description 70
- 235000008390 olive oil Nutrition 0.000 claims abstract description 68
- 210000002966 serum Anatomy 0.000 claims abstract description 56
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 52
- 230000003647 oxidation Effects 0.000 claims abstract description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 42
- 230000000694 effects Effects 0.000 claims abstract description 39
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 37
- 230000036542 oxidative stress Effects 0.000 claims abstract description 35
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 27
- 239000008157 edible vegetable oil Substances 0.000 claims abstract description 22
- 150000002632 lipids Chemical class 0.000 claims abstract description 21
- 239000000828 canola oil Substances 0.000 claims abstract description 20
- 235000019519 canola oil Nutrition 0.000 claims abstract description 20
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 18
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 18
- 210000000497 foam cell Anatomy 0.000 claims abstract description 14
- 230000036765 blood level Effects 0.000 claims abstract description 13
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 230000002939 deleterious effect Effects 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 235000019198 oils Nutrition 0.000 claims description 84
- 235000019197 fats Nutrition 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 35
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 32
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 32
- 235000005911 diet Nutrition 0.000 claims description 32
- 230000000378 dietary effect Effects 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 235000013305 food Nutrition 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 150000004665 fatty acids Chemical group 0.000 claims description 15
- 235000021323 fish oil Nutrition 0.000 claims description 14
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 13
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 11
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 9
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 8
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 8
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 8
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 8
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 8
- 235000016709 nutrition Nutrition 0.000 claims description 8
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 8
- 239000005642 Oleic acid Substances 0.000 claims description 7
- 229940076810 beta sitosterol Drugs 0.000 claims description 7
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 7
- 229950005143 sitosterol Drugs 0.000 claims description 7
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 6
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 claims description 6
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 6
- 235000004420 brassicasterol Nutrition 0.000 claims description 6
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical group CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims description 6
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 6
- 229960004488 linolenic acid Drugs 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- 235000016831 stigmasterol Nutrition 0.000 claims description 6
- 229940032091 stigmasterol Drugs 0.000 claims description 6
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 6
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims description 5
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 5
- 235000019482 Palm oil Nutrition 0.000 claims description 5
- 235000021314 Palmitic acid Nutrition 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 208000026758 coronary atherosclerosis Diseases 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 5
- 230000009931 harmful effect Effects 0.000 claims description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 5
- 239000002540 palm oil Substances 0.000 claims description 5
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 4
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 4
- 235000019485 Safflower oil Nutrition 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- 239000008163 avocado oil Substances 0.000 claims description 4
- 235000021302 avocado oil Nutrition 0.000 claims description 4
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 claims description 4
- 235000014121 butter Nutrition 0.000 claims description 4
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 4
- 235000019868 cocoa butter Nutrition 0.000 claims description 4
- 229940110456 cocoa butter Drugs 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 4
- 235000005713 safflower oil Nutrition 0.000 claims description 4
- 239000003813 safflower oil Substances 0.000 claims description 4
- 239000008159 sesame oil Substances 0.000 claims description 4
- 235000011803 sesame oil Nutrition 0.000 claims description 4
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- 229960004274 stearic acid Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 235000020510 functional beverage Nutrition 0.000 claims description 2
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims 7
- 239000006260 foam Substances 0.000 claims 1
- 239000003925 fat Substances 0.000 abstract description 32
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 18
- 238000011282 treatment Methods 0.000 abstract description 7
- 229940013317 fish oils Drugs 0.000 abstract 1
- 239000000902 placebo Substances 0.000 description 25
- 229940068196 placebo Drugs 0.000 description 25
- 240000007817 Olea europaea Species 0.000 description 20
- 150000002148 esters Chemical class 0.000 description 19
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 18
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 18
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 18
- 235000006008 Brassica napus var napus Nutrition 0.000 description 18
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 18
- 244000188595 Brassica sinapistrum Species 0.000 description 18
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 18
- 230000003078 antioxidant effect Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 235000002378 plant sterols Nutrition 0.000 description 16
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 15
- 235000014593 oils and fats Nutrition 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- 102000005862 Angiotensin II Human genes 0.000 description 11
- 101800000733 Angiotensin-2 Proteins 0.000 description 11
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 11
- 238000008214 LDL Cholesterol Methods 0.000 description 11
- 229950006323 angiotensin ii Drugs 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 150000002978 peroxides Chemical class 0.000 description 11
- 102000004895 Lipoproteins Human genes 0.000 description 10
- 108090001030 Lipoproteins Proteins 0.000 description 10
- 229940068065 phytosterols Drugs 0.000 description 10
- 108010028554 LDL Cholesterol Proteins 0.000 description 9
- 230000003859 lipid peroxidation Effects 0.000 description 9
- 210000004303 peritoneum Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 235000015112 vegetable and seed oil Nutrition 0.000 description 8
- 239000008158 vegetable oil Substances 0.000 description 8
- 229930182558 Sterol Natural products 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 235000003702 sterols Nutrition 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 230000003143 atherosclerotic effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 4
- 108010009043 arylesterase Proteins 0.000 description 4
- 102000028848 arylesterase Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 229940049953 phenylacetate Drugs 0.000 description 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 4
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 3
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 3
- 101710095339 Apolipoprotein E Proteins 0.000 description 3
- 102100029470 Apolipoprotein E Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000004722 NADPH Oxidases Human genes 0.000 description 3
- 108010002998 NADPH Oxidases Proteins 0.000 description 3
- 229920003189 Nylon 4,6 Polymers 0.000 description 3
- 101000942681 Rattus norvegicus Clusterin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical class COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 2
- MCWVPSBQQXUCTB-UHFFFAOYSA-N (24Z)-5alpha-Stigmasta-7,24(28)-dien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(=CC)C(C)C)CCC33)C)C3=CCC21 MCWVPSBQQXUCTB-UHFFFAOYSA-N 0.000 description 2
- 101150037123 APOE gene Proteins 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- LGJMUZUPVCAVPU-ANOYILKDSA-N (3s,8r,9s,10s,13r,14s,17r)-17-[(2r,5s)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1CC2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 LGJMUZUPVCAVPU-ANOYILKDSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- DRAWQKGUORNASA-CLFAGFIQSA-N 1,3-dioleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COC(=O)CCCCCCC\C=C/CCCCCCCC DRAWQKGUORNASA-CLFAGFIQSA-N 0.000 description 1
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DRAWQKGUORNASA-UHFFFAOYSA-N Anticancer Glycerol Ester PMV70P691-119 Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCC=CCCCCCCCC DRAWQKGUORNASA-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- YVDXIVLWTCSVDW-JXMNSIJESA-N [(3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] (Z)-octadec-9-enoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CC[C@@H](CC)C(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 YVDXIVLWTCSVDW-JXMNSIJESA-N 0.000 description 1
- FBQNVDGEJMFTTK-FPTIKDCHSA-N [(3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] (Z)-octadec-9-enoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)\C=C\[C@@H](CC)C(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 FBQNVDGEJMFTTK-FPTIKDCHSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- QEXVJKPQWBLYFH-UHFFFAOYSA-N beta-sitosteryl oleate Natural products CCCCCCCCC=CCCCCCCCCOC1CCC2(C)C3CCC4(C)C(CCC4C3CC=C2C1)C(C)CCC(CC)C(C)C QEXVJKPQWBLYFH-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011018 current good manufacturing practice Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010462 extra virgin olive oil Substances 0.000 description 1
- 235000021010 extra-virgin olive oil Nutrition 0.000 description 1
- 239000012632 extractable Substances 0.000 description 1
- 229940114123 ferulate Drugs 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009884 interesterification Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- CBFCDTFDPHXCNY-UHFFFAOYSA-N octyldodecane Natural products CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000899 pressurised-fluid extraction Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000207 pro-atherogenic effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- ZFMRLFXUPVQYAU-UHFFFAOYSA-N sodium 5-[[4-[4-[(7-amino-1-hydroxy-3-sulfonaphthalen-2-yl)diazenyl]phenyl]phenyl]diazenyl]-2-hydroxybenzoic acid Chemical compound C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C(C=C4C=CC(=CC4=C3O)N)S(=O)(=O)O)N=NC5=CC(=C(C=C5)O)C(=O)O.[Na+] ZFMRLFXUPVQYAU-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 125000005314 unsaturated fatty acid group Chemical group 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Abstract
Description
본 발명에서 사용된 오일의 조성 | ||||
오일 구성성분% (W/W) | 캐놀라 멀트오일 | 올리브 멀트오일 (엔지모테크 (Enzymotec) FG S7/1.75) |
생선 멀트오일 |
피토스테롤 에스테르 강화 올리브유 |
피토스테롤 에스테르 | 26 | 28.5 | 22.12 | 18 |
모노글리세리드 | 2.1 | 1.48 | 4.72 | 0.31 |
디글리세리드 | 14.9 | 14.62 | 20.02 | 0.81 |
트리글리세리드 | 46.9 | 48.9 | 40.3 | |
유리 스테롤 | 3.1 | 1.5 | 5.2 | 0.2 |
FFA | 7 | 5 | 5 | 3 |
글리세롤 | N.D. | N.D. | 2.6 | N.D. |
브라씨카스테롤 | 0.54 | 0.46 | 0.82 | N.D. |
캄페스테롤 | 5.43 | 4.58 | 4.93 | 0.009 |
스티그마스테롤 | 2.84 | 3.86 | 3.25 | 0.00142 |
베타시토스테롤 | 8.9 | 8.41 | 8.1 | 0.166 |
Claims (52)
- 오일, 지방, 또는 오일 및 지방의 혼합물 중에 용해되거나 분산된 디아실글리세롤류 (DAG); 및 피토스테롤 지방산 에스테르류, 피토스탄올 지방산 에스테르류, 또는 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 혼합물 (PSE)의 배합물을 포함하며,상기 오일은 천연 오일, 식용 오일, 또는 천연 오일 및 식용 오일의 혼합물이며, 상기 지방은 천연 지방이고,상기 피토스테롤 지방산 에스테르류, 피토스탄올 지방산 에스테르류, 또는 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 혼합물의 양이 20 중량% 내지 99 중량%이고,콜레스테롤 및 트리글리세리드 둘 다의 혈액 수준을 감소시키고, 혈청 산화 수준, 혈청 저밀도 지단백질(LDL) 산화 수준 및 대식세포 산화 수준을 저하시키고, 포말 세포의 형성을 억제하고, 지질 유도된 산화성 스트레스에 의해 발생된 해로운 영향을 방지하는 것 중의 하나 이상을 위한 식용 조성물을 함유한 식이 영양제.
- 제1항에 있어서, 상기 피토스테롤 지방산 에스테르류, 피토스탄올 지방산 에스테르류, 또는 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 혼합물의 양이 20 중량% 내지 50중량%인 식이 영양제.
- 제2항에 있어서, 상기 피토스테롤 지방산 에스테르류, 피토스탄올 지방산 에스테르류, 또는 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 혼합물의 양이 20 중량% 내지 35중량%인 식이 영양제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 디아실글리세롤류의 양이 7 중량% 내지 48 중량%인 식이 영양제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 디아실글리세롤류의 양이 10 중량% 내지 22 중량%인 식이 영양제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 식이 영양제는 식품 보충제 또는 식료품인 것을 특징으로 하는 식이 영양제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 디아실글리세롤류는 1,3-디아실글리세롤류인 식이 영양제.
- 삭제
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 오일이 올리브유, 대두유, 해바라기유, 홍화유, 캐놀라유, 야자유, 아보카도유, 참깨유 및 어유 중의 하나인 식이 영양제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 오일이 올리브유, 캐놀라유 또는 어유인 식이 영양제.
- 삭제
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 지방이 버터 지방, 무수 유지방, 코코아 버터 및 라드 중의 하나인 식이 영양제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 디아실글리세롤류의 지방산 잔기가 상기 디아실글리세롤류가 유도되는 오일의 지방산 잔기에 상응하는 것인 식이 영양제.
- 제13항에 있어서, 상기 지방산 잔기가 올레산, 팔미트산, 팔미트올레산, 스테아르산, 리놀레산, 리놀렌산, 도코사헥사엔산, 에이코사펜타엔산 및 에이코산산 잔기 중의 하나인 식이 영양제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 피토스테롤 지방산 에스테르류가 스티그마스테롤, 시토스테롤, 베타-시토스테롤, 브라씨카스테롤, 캄페스테롤, 5-아베나스테롤의 지방산 에스테르, 이들의 이성질체 및 이들의 유도체로 구성되는 군으로부터 선택되는 하나 이상인 식이 영양제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 조성물이 영양 조성물의 통상적인 성분을 추가로 포함하는 식이 영양제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 조성물 중의 상기 디아실글리세롤류 대 상기 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 하나 이상인 것의 몰비가 1:5 내지 5:1인 식이 영양제.
- 제17항에 있어서, 상기 조성물 중의 상기 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 하나 이상인 것 대 상기 디아실글리세롤류의 몰비가 2:1인 식이 영양제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 피토스테롤 지방산 에스테르류, 피토스탄올 지방산 에스테르류, 또는 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 혼합물의 총량 (중량%) 대 디아실글리세롤류의 총량 (중량%) 사이의 비율이 1.1, 1.75 및 1.95 중 하나인 식이 영양제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 조성물이 올리브유, 캐놀라유 및 어유 중 어느 하나 중에 용해되거나 분산된 15 중량% 1, 3-디아실글리세롤류, 및 전체 25 중량%의 피토스테롤 지방산 에스테르류, 피토스탄올 지방산 에스테르류, 또는 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 혼합물로 이루어진 것인 식이 영양제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 심혈관 장애 및 이와 관련된 질환을 치료하고 예방하는 것 중의 하나 이상을 위한 식이 영양제.
- 제21항에 있어서, 상기 장애 또는 질환은 관상동맥성 심장 질환, 죽상동맥경화증, 및 다른 질환에 의해 유도되거나 발현되는 심혈관 장애 중 하나인 식이 영양제.
- 삭제
- 삭제
- 오일, 지방, 또는 오일 및 지방의 혼합물 중에 용해되거나 분산된 디아실글리세롤류 (DAG); 및 피토스테롤 지방산 에스테르류, 피토스탄올 지방산 에스테르류, 또는 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 혼합물 (PSE)의 배합물을 포함하고,상기 오일은 천연 오일, 식용 오일, 또는 천연 오일 및 식용 오일의 혼합물이며, 상기 지방은 천연 지방이고,상기 피토스테롤 지방산 에스테르류, 피토스탄올 지방산 에스테르류, 또는 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 혼합물의 양이 20 중량% 내지 99 중량%이고,콜레스테롤 및 트리글리세리드 둘 다의 혈액 수준을 감소시키고, 혈청 산화 수준, 혈청 저밀도 지단백질(LDL) 산화 수준 및 대식세포 산화 수준을 저하시키고, 포말 세포의 형성을 억제하고, 지질 유도된 산화성 스트레스에 의해 발생된 해로운 영향을 방지하는 것 중의 하나 이상을 위한 경구 투여가능한 제약 조성물.
- 제25항에 있어서, 상기 피토스테롤 지방산 에스테르류, 피토스탄올 지방산 에스테르류, 또는 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 혼합물의 양이 20 중량% 내지 50 중량%인 제약 조성물.
- 제26항에 있어서, 상기 피토스테롤 지방산 에스테르류, 피토스탄올 지방산 에스테르류, 또는 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 혼합물의 양이 20 중량% 내지 35 중량%인 제약 조성물.
- 제25항 내지 제27항 중 어느 한 항에 있어서, 상기 디아실글리세롤류의 양이 7 중량% 내지 48 중량%인 제약 조성물.
- 제25항 내지 제27항 중 어느 한 항에 있어서, 상기 디아실글리세롤류의 양이 10 중량% 내지 22 중량%인 제약 조성물.
- 제25항 내지 제27항 중 어느 한 항에 있어서, 상기 제약 조성물은 제약상 허용가능한 첨가제, 희석제, 부형제 및 담체로 구성되는 군으로부터 선택된 하나 이상을 추가로 포함하는 제약 조성물.
- 제25항 내지 제27항 중 어느 한 항에 있어서, 심혈관 장애 및 이와 관련된 질환을 치료하고 예방하는 것 중의 하나 이상을 위한 제약 조성물.
- 제31항에 있어서, 상기 장애 또는 질환은 관상동맥성 심장 질환, 죽상동맥경화증, 및 다른 질환에 의해 유도되거나 발현되는 심혈관 장애 중의 하나인 제약 조성물.
- 제32항에 있어서, 상기 다른 질환은 당뇨병인 제약 조성물.
- 제33항에 있어서, 상기 다른 질환은 제II형 당뇨병인 제약 조성물.
- 삭제
- 제25항 내지 제27항 중 어느 한 항에 있어서, 상기 오일이 올리브유, 대두유, 해바라기유, 홍화유, 캐놀라유, 야자유, 참깨유, 아보카도유 및 어유 중의 하나인 제약 조성물.
- 제25항 내지 제27항 중 어느 한 항에 있어서, 상기 오일이 올리브유, 캐놀라유 또는 어유인 제약 조성물.
- 삭제
- 제25항 내지 제27항 중 어느 한 항에 있어서, 상기 지방이 버터 지방, 무수 유지방, 코코아 버터 및 라드 중의 하나인 제약 조성물.
- 제25항 내지 제27항 중 어느 한 항에 있어서, 디아실글리세롤류의 지방산 잔기가 상기 디아실글리세롤류가 유도되는 오일의 지방산 잔기에 상응하는 제약 조성물.
- 제40항에 있어서, 상기 지방산 잔기가 올레산, 팔미트산, 팔미트올레산, 스테아르산, 리놀레산, 리놀렌산, 도코사헥사엔산, 에이코사펜타엔산 및 에이코산산 잔기 중의 하나인 제약 조성물.
- 제25항 내지 제27항 중 어느 한 항에 있어서, 피토스테롤 지방산 에스테르류가 스티그마스테롤, 시토스테롤, 베타-시토스테롤, 브라씨카스테롤, 캄페스테롤, 5-아베나스테롤의 지방산 에스테르, 이들의 이성질체 및 이들의 유도체로 구성되는 군으로부터 선택되는 하나 이상인 제약 조성물.
- 제25항 내지 제27항 중 어느 한 항에 있어서, 상기 조성물 중의 상기 디아실글리세롤류 대 상기 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 하나 이상인 것의 몰비가 1:5 내지 5:1인 제약 조성물.
- 제43항에 있어서, 상기 조성물 중의 상기 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 하나 이상인 것 대 상기 디아실글리세롤류의 몰비가 2:1인 제약 조성물.
- 콜레스테롤 및 트리글리세리드 둘 다의 혈액 수준을 감소시키고, 혈청 산화 수준, 혈청 저밀도 지단백질 산화 수준 및 대식세포 산화 수준을 저하시키고, 포말 세포의 형성을 억제하고, 지질 유도된 산화성 스트레스에 의해 발생된 해로운 영향을 방지하는 것 중의 하나 이상의 효과를 갖는 것을 특징으로 하는, 올리브유 중에 용해되거나 분산된 15 중량% 디아실글리세롤류 및 전체 25 중량%의 피토스테롤 지방산 에스테르류, 피토스탄올 지방산 에스테르류, 또는 피토스테롤 지방산 에스테르류 및 피토스탄올 지방산 에스테르류의 혼합물로 이루어진, 콜레스테롤 및 트리글리세리드 둘 다의 혈액 수준을 감소시키고, 저밀도 지단백질 산화를 감소시키는 것 중의 하나 이상을 위한 제약 조성물.
- 제45항에 있어서, 상기 디아실글리세롤류는 1,3-디아실글리세롤류인 제약 조성물.
- 제45항에 있어서, 심혈관 장애 및 이와 관련된 질환을 치료하고 예방하는 것 중의 하나 이상을 위한 제약 조성물.
- 제47항에 있어서, 상기 장애 또는 질환은 관상동맥성 심장 질환, 죽상동맥경화증, 및 다른 질환에 의해 유도되거나 발현되는 심혈관 장애 중의 하나인 제약 조성물.
- 제48항에 있어서, 상기 다른 질환은 당뇨병인 제약 조성물.
- 제49항에 있어서, 상기 다른 질환은 제II형 당뇨병인 제약 조성물.
- 제25항 내지 제27항, 제45항 내지 제50항 중 어느 한 항에 있어서, 콜레스테롤 및 트리글리세리드 둘 다의 혈액 수준, 혈청 산화성 스트레스, 대식세포에 의한 산화성 저밀도 지단백질 섭취, 대식세포 산화 상태, 포말 세포 형성 및 지질 유도된 산화성 스트레스에 의해 발생된 해로운 영향의 감소 및 방지 중의 하나 이상을 위한 제약 조성물.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 기능성 식품, 기능성 음료 및 식이 보충제 중 어느 하나의 제조에서 사용하기 위한 식이 영양제.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL154381 | 2003-02-10 | ||
IL15438103A IL154381A0 (en) | 2003-02-10 | 2003-02-10 | A composition for reducing blood cholesterol and triglycerides |
IL155136 | 2003-03-27 | ||
IL15513603A IL155136A0 (en) | 2003-02-10 | 2003-03-27 | A composition for reducing blood cholesterol and triglycerides |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050121672A KR20050121672A (ko) | 2005-12-27 |
KR100959704B1 true KR100959704B1 (ko) | 2010-05-25 |
Family
ID=32599150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057014677A KR100959704B1 (ko) | 2003-02-10 | 2004-02-10 | 콜레스테롤 및 트리글리세리드의 감소에 사용하기 위한디아실글리세롤 및 피토스테롤 에스테르 강화 오일 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060052351A1 (ko) |
EP (1) | EP1596670B1 (ko) |
JP (1) | JP2006517222A (ko) |
KR (1) | KR100959704B1 (ko) |
AU (2) | AU2004210244C1 (ko) |
BR (1) | BRPI0407338B8 (ko) |
CA (1) | CA2515290A1 (ko) |
DK (1) | DK1596670T3 (ko) |
HK (1) | HK1086168A1 (ko) |
IL (2) | IL155136A0 (ko) |
NZ (1) | NZ541887A (ko) |
SI (1) | SI1596670T1 (ko) |
WO (1) | WO2004069150A2 (ko) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL147942A0 (en) * | 2002-01-31 | 2002-08-14 | Enzymotec Ltd | Method of fractionation of phytosterol esters in oil and products obtained thereby |
US20060233863A1 (en) | 2003-02-10 | 2006-10-19 | Enzymotec Ltd. | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy |
US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
GB0513881D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
GB0329667D0 (en) * | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
US20090232916A1 (en) * | 2004-08-09 | 2009-09-17 | Avidor Shulman | Food products for diabetics |
JP5118965B2 (ja) * | 2004-08-10 | 2013-01-16 | エンジモテック リミテッド | 植物成分を必要とする治療方法 |
US20060286280A1 (en) * | 2005-06-09 | 2006-12-21 | Bradford Lisa L | Compositions containing protein and DAG oil and methods for making them |
GB0512726D0 (en) * | 2005-06-22 | 2005-07-27 | Btg Int Ltd | Multiple sclerosis therapy and diagnosis |
GB0513888D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
GB0513883D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Diagnosis of Atherosclerosis |
JP4852296B2 (ja) * | 2005-10-27 | 2012-01-11 | 花王株式会社 | 血管炎症候群予防・治療剤 |
CN102176834A (zh) * | 2008-08-11 | 2011-09-07 | 阿邦达营养学股份有限公司 | 富含二酰基甘油的脂肪、油和功能性食物 |
KR101760953B1 (ko) * | 2008-09-04 | 2017-07-24 | 아밀린 파마슈티칼스, 엘엘씨. | 비-수성 담체를 이용한 서방성 제형물 |
WO2010118362A1 (en) | 2009-04-09 | 2010-10-14 | The Regents Of The University Of Colorado, A Body Corporate | Methods and compositions for inducing physiological hypertrophy |
KR100946641B1 (ko) * | 2010-01-19 | 2010-03-09 | 연세대학교 산학협력단 | 신코닌을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물 |
JP2014529596A (ja) * | 2011-08-16 | 2014-11-13 | アボット・ラボラトリーズAbbott Laboratories | 食事を変換する方法 |
JP5925638B2 (ja) | 2011-08-22 | 2016-05-25 | 花王株式会社 | 油脂組成物 |
EP3023011B1 (en) | 2013-06-24 | 2017-05-31 | Mottainai Biomass Research Corporation | Natural binder derived from lipophilic pith fibers (ground stem or stalk internal fibers) separated from sunflower stems or stalks for processed foods and processed foods containing the same. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020045000A1 (en) | 2000-07-19 | 2002-04-18 | Kao Corporation | Edible oil and production process thereof |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4064236A (en) | 1975-12-23 | 1977-12-20 | Merck & Co., Inc. | Peptide carbazates and pharmaceutical composition |
DE3117934A1 (de) | 1981-05-06 | 1982-12-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Neues peptid, verfahren zu seiner gewinnung und dieses enthaltendes arzneimittel |
JPS58500638A (ja) * | 1981-05-07 | 1983-04-28 | ユニリ−バ− ナ−ムロ−ゼ ベンノ−トシヤ−プ | エステルの合成法 |
JPS608225A (ja) | 1983-06-29 | 1985-01-17 | Kowa Co | 腸管吸収医薬組成物 |
JPS60136596A (ja) | 1983-12-26 | 1985-07-20 | Suntory Ltd | ペプチド及びこれを有効成分とする利尿剤 |
EP0231039B1 (en) | 1986-01-14 | 1992-01-08 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Process for preparing immunological complexes and pharmaceutical composition containing these complexes |
US5164372A (en) | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
US5439688A (en) | 1989-07-28 | 1995-08-08 | Debio Recherche Pharmaceutique S.A. | Process for preparing a pharmaceutical composition |
CA2050425A1 (en) | 1990-09-03 | 1992-03-04 | Yoshiaki Uda | Pharmaceutical composition and its mucous use |
US5298246A (en) | 1991-01-09 | 1994-03-29 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Stable pharmaceutical composition and method for its production |
JP2925391B2 (ja) | 1992-01-09 | 1999-07-28 | サントリー株式会社 | Ards治療用医薬組成物 |
RU2107692C1 (ru) | 1995-06-07 | 1998-03-27 | Дейгин Владислав Исакович | Пептид и способ его получения |
JPH0827018A (ja) | 1994-07-22 | 1996-01-30 | Sanwa Kagaku Kenkyusho Co Ltd | 生理活性ペプチド又は蛋白質を含有する薬剤組成物 |
US5843499A (en) * | 1995-12-08 | 1998-12-01 | The United States Of America As Represented By The Secretary Of Agriculture | Corn fiber oil its preparation and use |
FR2750606B1 (fr) * | 1996-07-03 | 1999-01-29 | Maurel Sante | Complexes organometalliques a base de sitosterols et de diglycerides et compositions pharmaceutiques en contenant |
US6046022A (en) * | 1996-09-30 | 2000-04-04 | Peking University | Methods and compositions employing red rice fermentation products |
JPH10231495A (ja) * | 1996-12-20 | 1998-09-02 | Jiyanifu Tec:Kk | 抗肥満および内臓蓄積脂肪低減化機能を有する物質、およびその用途 |
DE69826592T2 (de) * | 1997-08-22 | 2006-02-23 | Unilever N.V. | Verfahren zur Herstellung von Stanolestern |
AU8760898A (en) * | 1997-09-24 | 1999-04-12 | Enzymotec Ltd. | Surfactant-lipase complex immobilized on insoluble matrix |
BR9904796B1 (pt) * | 1998-03-24 | 2012-02-22 | composição de óleo ou gordura contendo fitosterol, composição de óleo ou gordura, produto alimentar, produto de bebida, e óleo de mesa de cozimento. | |
US6025348A (en) * | 1998-04-30 | 2000-02-15 | Kao Corporation | Oil and fat composition containing phytosterol |
FI111513B (fi) * | 1998-05-06 | 2003-08-15 | Raisio Benecol Oy | Uudet fytosteroli- ja fytostanolirasvahappoesterikoostumukset, niitä sisältävät tuotteet sekä menetelmät niiden valmistamiseksi |
US6277431B1 (en) * | 1998-10-14 | 2001-08-21 | Redeem, Inc. | Anticholesterolemic edible oil |
US6129945A (en) * | 1998-12-10 | 2000-10-10 | Michael E. George | Methods to reduce free fatty acids and cholesterol in anhydrous animal fat |
US6080173A (en) * | 1999-05-26 | 2000-06-27 | Idx Medical Ltd. | Tissue punching instrument |
US6365211B1 (en) * | 1999-06-18 | 2002-04-02 | The Procter & Gamble Co. | Cooking aid with reduced foaming |
JP2003512850A (ja) * | 1999-11-03 | 2003-04-08 | フォーブス メディ−テック インコーポレーテッド | 食用油または脂肪と、その中に実質的に溶解したフィトステロールおよび/またはフィロスタノールとを含む組成物、その製造方法、並びに心血管疾患およびその根底にある状態を治療または予防することにおけるその使用 |
US20020132035A1 (en) * | 2001-01-10 | 2002-09-19 | Dov Tamarkin | Synthetic fat composition |
JP4911815B2 (ja) * | 2000-04-28 | 2012-04-04 | 株式会社Adeka | 植物ステロール含有油脂組成物 |
JP4031219B2 (ja) * | 2000-08-08 | 2008-01-09 | 花王株式会社 | 油脂組成物 |
US7008661B2 (en) * | 2000-08-08 | 2006-03-07 | Kao Corporation | Oil/fat composition |
KR20080064882A (ko) * | 2000-11-13 | 2008-07-09 | 니폰스이산가이샤 | 에이코사펜타엔산(이피에이) 고농도 함유 두유류 및 그제조방법 |
SE523094C2 (sv) * | 2001-01-11 | 2004-03-30 | Karlshamns Ab | Förfarande för framställning av en fettkomposition som innehåller sterolestrar, fria steroler och glycerider, fettkomposition framställd genom förfarandet samt fettkompositionens användning |
JP3746270B2 (ja) * | 2001-01-29 | 2006-02-15 | エムエルビー、エンタープライゼス、エルエルシー | 抗コレステロール血症食用油 |
US6667068B2 (en) * | 2001-01-29 | 2003-12-23 | Kraft Foods Holdings, Inc. | Method for preparing solid milk product |
GB0104074D0 (en) * | 2001-02-19 | 2001-04-04 | Novartis Ag | New composition |
JP4995377B2 (ja) * | 2001-04-26 | 2012-08-08 | 花王株式会社 | 油脂組成物 |
GB0114014D0 (en) * | 2001-06-08 | 2001-08-01 | Novartis Nutrition Ag | Compostion and use |
IL147942A0 (en) * | 2002-01-31 | 2002-08-14 | Enzymotec Ltd | Method of fractionation of phytosterol esters in oil and products obtained thereby |
US20060233863A1 (en) * | 2003-02-10 | 2006-10-19 | Enzymotec Ltd. | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy |
US20040219188A1 (en) * | 2003-05-02 | 2004-11-04 | Comer Gail M. | Composition and methods for nutritional management of patients with hepatic disease |
US20050032757A1 (en) * | 2003-08-06 | 2005-02-10 | Cho Suk H. | Nutritional supplements |
-
2003
- 2003-03-27 IL IL15513603A patent/IL155136A0/xx unknown
-
2004
- 2004-02-10 SI SI200432168T patent/SI1596670T1/sl unknown
- 2004-02-10 WO PCT/IL2004/000131 patent/WO2004069150A2/en active Search and Examination
- 2004-02-10 DK DK04709679.7T patent/DK1596670T3/da active
- 2004-02-10 KR KR1020057014677A patent/KR100959704B1/ko active IP Right Grant
- 2004-02-10 BR BRPI0407338A patent/BRPI0407338B8/pt not_active IP Right Cessation
- 2004-02-10 JP JP2006502637A patent/JP2006517222A/ja active Pending
- 2004-02-10 EP EP04709679.7A patent/EP1596670B1/en not_active Expired - Fee Related
- 2004-02-10 CA CA002515290A patent/CA2515290A1/en not_active Abandoned
- 2004-02-10 NZ NZ541887A patent/NZ541887A/en not_active IP Right Cessation
- 2004-02-10 AU AU2004210244A patent/AU2004210244C1/en not_active Ceased
-
2005
- 2005-08-01 IL IL170022A patent/IL170022A/en active IP Right Grant
- 2005-08-08 US US11/199,584 patent/US20060052351A1/en not_active Abandoned
-
2006
- 2006-05-22 HK HK06105873.5A patent/HK1086168A1/xx not_active IP Right Cessation
-
2009
- 2009-03-06 AU AU2009200897A patent/AU2009200897B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020045000A1 (en) | 2000-07-19 | 2002-04-18 | Kao Corporation | Edible oil and production process thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2004069150A2 (en) | 2004-08-19 |
AU2004210244B9 (en) | 2009-02-05 |
EP1596670A2 (en) | 2005-11-23 |
EP1596670B1 (en) | 2014-05-07 |
CA2515290A1 (en) | 2004-08-19 |
KR20050121672A (ko) | 2005-12-27 |
NZ541887A (en) | 2007-05-31 |
BRPI0407338A (pt) | 2006-01-10 |
IL170022A (en) | 2015-11-30 |
AU2004210244A1 (en) | 2004-08-19 |
US20060052351A1 (en) | 2006-03-09 |
DK1596670T3 (da) | 2014-07-28 |
WO2004069150A3 (en) | 2004-09-23 |
SI1596670T1 (sl) | 2014-08-29 |
BRPI0407338B8 (pt) | 2021-05-25 |
HK1086168A1 (en) | 2006-09-15 |
BRPI0407338B1 (pt) | 2016-10-25 |
IL155136A0 (en) | 2003-10-31 |
JP2006517222A (ja) | 2006-07-20 |
AU2004210244C1 (en) | 2009-07-16 |
AU2009200897B2 (en) | 2011-12-08 |
AU2004210244B2 (en) | 2008-12-11 |
AU2009200897A1 (en) | 2009-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009200897B2 (en) | Oils enriched with diacylglycerols and phytosterol ester for use in the reduction of cholesterol and triglycerides | |
US8507466B2 (en) | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy | |
La Lastra et al. | Mediterrranean diet and health biological importance of olive oil | |
Aviram | Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants | |
Sankar et al. | A pilot study of open label sesame oil in hypertensive diabetics | |
KR101323513B1 (ko) | 의학적 증상의 치료에서의 사용을 위한 피토스테롤에스테르(들) 및 1,3-디글리세라이드(들)의 혼합물 | |
KR100678831B1 (ko) | 피토스테롤 및/또는 피토스타놀 유도체 | |
Soni et al. | Chronic study of diacylglycerol oil in rats | |
JP2002534445A (ja) | 血中コレステロール及び/又は血中トリグリセリドの低下方法 | |
JP2005527539A (ja) | 黒米からのアントシアニンの抽出方法およびその組成物 | |
Chovančíková et al. | Effects of hight–fat and Chlorella vulgaris feeding on changes in lipid metabolism in mice | |
EP2682116B1 (en) | Metabolic syndrome ameliorating agent | |
ES2398847T3 (es) | Composición que comprende uno o más fitoesteroles y/o fitoestanoles y glucomanano y usos de la composición para tratar trastornos de lípidos en individuos con y sin diabetes de tipo II | |
JP2006306812A (ja) | 好酸球浸潤抑制剤 | |
CN1809284B (zh) | 用于降低胆固醇和甘油三酯的富含二酰甘油和植物甾醇酯的油 | |
JPWO2011122389A1 (ja) | 糖尿病の予防又は治療用油脂組成物 | |
Kawabata et al. | Influences of stearidonic acid-enriched soybean oil on the blood and organ biochemical parameters in rats | |
da Silva Marineli et al. | Phytosterols: Biological effects and mechanisms of hypocholesterolemic action | |
Moghadasian et al. | Anti-atherogenic effects of phytosteryl oleates in apo-E deficient mice | |
US8993551B2 (en) | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof | |
EP2090176B1 (en) | Postprandial hyperglycemia-improving agent | |
Ho et al. | Beneficial effects of plant sterols/stanols-containing milk powder on lipid metabolism in hamsters | |
CA2538494C (en) | Composition for modulating blood parameters | |
Martchenko et al. | Physiologic effects of the maqui berry (Aristotelia chilensis): a focus on metabolic homeostasis | |
KR20120017498A (ko) | 바우미 상황버섯 유래의 폴리페놀 추출물을 유효성분으로 함유하는 동맥경화 예방 및 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130502 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140502 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150515 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170512 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180509 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190508 Year of fee payment: 10 |